Novo Nordisk’s Semaglutide Cuts BMI 13.5% in Children Under 12

Share on Social Media

Semaglutide reduces BMI in children aged 6 to under 12 years with obesity in the Phase 3 STEP Young trial.

NEJM reports a 13.5% BMI reduction with semaglutide versus a 2.7% increase with placebo in children aged 6 to under 12 in the STEP Young trial.

Written By: Anamika Koshti, PharmD

Reviewed By: Pharmacally Editorial Team

Semaglutide reduced body mass index (BMI) by 13.5% in children aged 6 to under 12 years with obesity in the Phase 3 STEP Young trial, compared with a 2.7% increase with placebo at week 68. The findings, published in The New England Journal of Medicine (NEJM) on November 16, 2026, provide clinical evidence for evaluating semaglutide in a younger paediatric population that currently has limited pharmacological treatment options.

Novo Nordisk’s previously reported in September 2026 topline announcement from the STEP Young trial. The subsequent publication in The New England Journal of Medicine provides the detailed clinical findings, including the primary BMI endpoint, secondary efficacy outcomes, treatment durability and safety profile.

Extending Semaglutide Treatment Below Age 12

Semaglutide is approved in the United States for obesity management in adults and adolescents, but not in children younger than 12 years. Previous clinical evidence from STEP TEENS demonstrated BMI reductions in adolescents aged 12 to under 18 years, while the SCALE Kids trial evaluated liraglutide in children aged 6 to under 12 years.

STEP Young addresses this evidence gap by evaluating once-weekly semaglutide in younger children with obesity. Novo Nordisk describes it as the first Phase 3 semaglutide study in this age group.

STEP Young Trial Design and Dosing

The double-blind, placebo-controlled Phase 3 trial randomized 167 children aged 6 to under 12 years with obesity, defined as BMI at or above the 95th percentile for age and sex, in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (112 participants) or placebo (55 participants).

Both groups received lifestyle interventions, including a reduced-calorie diet and increased physical activity. Semaglutide was initiated at 0.25 mg weekly and gradually escalated. The maximum dose was 1.7 mg for children weighing 45 to 60 kg at baseline and 2.4 mg for those weighing more than 60 kg, or the maximum tolerated dose.

Treatment continued for 104 weeks, followed by a seven-week washout period. The primary endpoint was percentage change in BMI from baseline to week 68. More than 85% of participants had class II or III obesity at baseline.

Primary and Secondary Efficacy Results

At week 68, BMI decreased by 13.5% with semaglutide and increased by 2.7% with placebo, representing an estimated between-group difference of 16.2 percentage points (95% CI, −19.4 to −12.9; P<0.001).

For the confirmatory secondary endpoint, 79% of children receiving semaglutide moved to a lower BMI category, compared with 23% receiving placebo (odds ratio, 7.8; 95% CI, 3.5–17.6; P<0.001). Additionally, 38% of children in the semaglutide group achieved a BMI below the obesity threshold, defined as the 95th percentile for age and sex, compared with 2% in the placebo group.

At week 104, BMI changes were −9.4% with semaglutide and +8.4% with placebo, maintaining a between-group difference of 17.8 percentage points. However, these later findings should be interpreted as secondary results rather than as the primary confirmatory evidence.

Additional Findings from the Efficacy Estimand

Novo Nordisk also reported an efficacy-estimand analysis assuming participants remained on assigned treatment without other weight-management interventions. Under this analysis, BMI decreased by 17.4% with semaglutide and increased by 2.2% with placebo at week 68.

Nearly 79% of semaglutide recipients achieved at least a 10% BMI reduction, while 40.4% were no longer classified as having obesity, compared with none in the placebo group. These supportive findings should be distinguished from the primary treatment-regimen analysis and interpreted with the limitations of multiplicity-unadjusted endpoints.

Safety and Tolerability

Adverse events occurred in 96% of participants receiving semaglutide and 93% receiving placebo. Gastrointestinal events were the most common adverse events and occurred more frequently with semaglutide, resulting in one treatment discontinuation.

Novo Nordisk reported no identified safety concerns relating to growth or pubertal development. Nevertheless, longer-term monitoring remains important to assess developmental outcomes and the durability of BMI reductions after treatment discontinuation.

Comparison With Earlier Paediatric Obesity Trials

The STEP Young findings can be considered alongside earlier trials evaluating GLP-1 receptor agonists in younger children and adolescents.

In SCALE Kids, once-daily liraglutide 3.0 mg reduced BMI by 5.8% at week 56, compared with a 1.6% increase with placebo, representing a between-group difference of 7.4 percentage points. The trial enrolled 82 children aged 6 to under 12 years.

In adolescents, STEP TEENS demonstrated a 16.1% BMI reduction with once-weekly semaglutide 2.4 mg at week 68, compared with a 0.6% increase with placebo, producing a 16.7-percentage-point treatment difference.

Although the numerical treatment difference in STEP Young was greater than that reported in SCALE Kids and close to the adolescent findings in STEP TEENS, these separate trials do not establish comparative superiority because their populations, designs and treatment durations differed.

Clinical Interpretation

STEP Young provides randomized Phase 3 evidence that semaglutide can substantially reduce BMI in children aged 6 to under 12 years with obesity when combined with lifestyle interventions. The 16.2-percentage-point difference from placebo is also numerically close to the treatment difference previously reported in adolescents in STEP TEENS.

However, the findings do not establish regulatory approval or routine clinical use in children younger than 12 years. Semaglutide remains unapproved for obesity treatment in this age group in the United States. Further regulatory evaluation and longer-term evidence addressing growth, pubertal development and treatment durability will be important in determining its potential role in paediatric obesity management.

Reference

Ania M. Jastreboff, M.D., Ph.D.  et al, Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age, New Eng J Med, Published November 16, 2026, DOI: 10.1056/NEJMoa2604058

A Research Study on How Well Semaglutide Helps Children and Teenagers with Excess Body Weight Lose Weight (STEP Young), ClinicalTrials.gov ID NCT05726227

About the Writer

Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.


Share on Social Media
Scroll to Top